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Abstract 
Purpose: Several studies investigated the efficacy of transplanting adipose-derived 
mesenchymal stem cells (ADMSCs) in the treatment of neuropathic pain in animals. 
However, these studies evaluated the effects of ADMSCs transplantation by assessing the 
mechanical allodynia but not spontaneous pain. Here, we verify whether ADMSCs 
transplantation improves spontaneous pain in a rat model of neuropathic pain. 
Methods: ADMSCs were isolated from rat adipose tissue and cultured. Chronic constriction 
injury (CCI) model rats were created by surgical maneuver. A total of 20 F344 rats underwent 
surgery and were divided into 2 groups, the ADMSCs group and the control group. One week 
after CCI surgery, ADMSCs were transplanted into the epineurium of the damaged nerve. 
The effects of ADMSCs transplantation were evaluated by the number of spontaneous 
pain-related behaviors and the degree of mechanical allodynia. The degree of mechanical 
allodynia was assessed with the von-Frey filament test.  
Results: No rats died during the experiments and all CCI model rats were established 
successfully. ADMSCs transplantation improved mechanical allodynia on and after 7-day 
post-transplantation and spontaneous pain on and after 21-day post-transplantation with the 
statistically significant differences. These improvement effects were observed until 6-week 
post-transplantation in mechanical allodynia and 5-week post-transplantation in spontaneous 
pain. 
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Conclusion: ADMSCs transplantation improved not only mechanical allodynia but also 
spontaneous pain. ADMSCs transplantation may be an effective treatment for neuropathic 
pain in clinical practice. 
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Introduction 
The prevalence of neuropathic pain is estimated to be 6.9–10% worldwide [1]. Only 
15-50% of patients with neuropathic pain exhibit mechanical allodynia [2], while almost 
100% of patients struggle with spontaneous pain [3]. Despite that the neuropathic pain can be 
a major burden, the current treatments include pharmacotherapy, physical therapy, cognitive 
therapy, interventional pain management, and other treatments that are still insufficient [4, 5]. 
Recently, the effects of the mesenchymal stem cells (MSCs) transplantation as the treatment 
for neuropathic pain were examined and verified [6, 7]. In animal experiments, MSCs 
transplantation was shown to improve mechanical allodynia in neuropathic pain through their 
anti-inflammatory and immunomodulatory properties [8]. Various types of MSCs exist such 
as bone marrow derived MSCs, adipose-derived MSCs (ADMSCs), and umbilical 
cord-derived MSCs. ADMSCs are advantageous for clinical applications because they can be 
obtained less invasively and in large quantities compared to other MSCs types. While several 
studies examined the effects of ADMSCs transplantation for the treatment of neuropathic 
pain [9-12], these studies evaluated that effects by assessing mechanical allodynia but not 
spontaneous pain. Methods to evaluate mechanical allodynia in animal experiments are 
similar to those used for mechanical allodynia evaluation in clinical practice. For example, 
the von-Frey filament test used in animal experiments is also used to assess mechanical 
allodynia in humans [13]. 
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As mentioned above, almost all patients with neuropathic pain have spontaneous pain. 
Evaluating spontaneous pain improvement by the treatment in animal experiments would be 
more directly applicable to the judgement of the treatments effectiveness for neuropathic pain 
in human than evaluating mechanical allodynia improvement.  
In this study, we hypothesized that the transplantation of ADMSCs would improve not only 
mechanical allodynia but also spontaneous pain. To verify this hypothesis, we transplanted 
syngeneic ADMSCs into the lesions of chronic constriction injury (CCI) model rats and 
assessed its efficacy to the spontaneous pain improvement with the method described by 
Kawasaki et al [14] and to the mechanical allodynia improvement with the von-Frey filament 
test. 
 
Methods 
The research protocol was approved by the Animal Research Committee of Dokkyo 
Medical University (Animal Research Approval Number 1017). 9-week-old Male F344 rats 
weighing 180–220 g (Japan SLC, Shizuoka, Japan) were used. The rats were kept 
individually in cages under standard laboratory conditions at 23±2°C and a humidity of 
50±10% with a 12-hour light/dark cycle. All animals were weighed once a week and checked 
for health status. The rats were acclimated in the cages for at least 1 week before the 
beginning of the experiment.   
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A block of adipose tissue was removed from F344 rats those that had not undergone the 
CCI surgery. ADMSCs were isolated from the adipose tissue and passaged 2–4 times to 
prepare for transplantation. CCI surgery was performed on 20 rats according to a previously 
described method by Bennett and Xie [15]. Rats were randomly assigned to 2 groups: the 
ADMSCs transplantation group and the control group (10 for each group). One week after 
the CCI surgery, the ADMSCs transplantation group rats were transplanted with ADMSCs 
into the epineurium of the lesions. The control group rats were only injected with phosphate 
buffered saline (PBS) into the epineurium of the lesions. Spontaneous pain and mechanical 
allodynia were evaluated before ADMSC transplantation and then weekly until week 6 of  
post-transplantation. All experiments were performed between 10:00 and 20:00. The details 
of each of these steps are described below. 
Isolation and culture of ADMSCs 
Adipose tissue was removed from the inguinal and abdominal regions of 9-week-old male 
F344 rats. The tissue was thoroughly washed with PBS and then blood vessels and 
connective tissue were removed. The tissue was subsequently minced. The minced tissue was 
added to a solution containing 0.1% collagenase type 1 (Sigma, St. Louis, MO, USA) and 
0.2% dispase (Sigma) and mixed by shaking at 37°C for 60 minutes. Digested tissue was 
filtered through a 100 µm filter. The filtrate was centrifuged at 1200 rpm for 5 minutes. The 
isolated cell pellet was washed with PBS and centrifuged again. A cell suspension containing 
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the isolated ADMSCs was cultured in basic medium (Dulbecco’s Modified Eagle’s Medium) 
containing 10% fetal bovine serum and 2% penicillin-streptomycin at 37°C and 5% CO2. 
Cells at passages 2–4 were used as ADMSCs for transplantation. 
CCI model rats 
The CCI surgery was performed as described by Bennett and Xie[15]. All animals were 
anesthetized with isoflurane. The fascia between the gluteal muscles and biceps femoris 
muscle was opened to expose the left sciatic nerve. Proximal to the trifurcation of the sciatic 
nerve, four 4/0 chromic gut ligatures were loosely tied around the nerve with the intervals of 
1mm. The ligatures were constricted to approximately a third of the diameter of the nerve. 
The fascia and skin were closed with 4/0 nylon thread. 
ADMSCs transplantation 
ADMSCs were transplanted 7 days after the CCI surgery. All animals were anesthetized 
with isoflurane. To avoid additional nerve damage, the previous scar was carefully reopened 
to expose the sciatic nerve. Under microscopic magnification, 1.0×10⁶ cells mixed with 50 
µL of PBS were transplanted into the epineurium with a 32G needle. In the control group, 50 
µL of PBS was injected into the epineurium. The fascia and skin were closed with 4-0 nylon 
thread. 
Assessment of spontaneous pain by automatically measuring the number of limb 
movements including spontaneous pain-related behaviors [14] 
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This assessment was performed according to the method previously proposed by 
Kawasaki-Yatsugi et al. [14]. Magnets were implanted at the timing of CCI surgery. A 
Teflon-coated columnar magnet (1 mm in diameter, 3 mm long; SCT-MAG-TF, 
Neuroscience Inc., Tokyo, Japan) was implanted under the dorsal skin of the ipsilateral foot. 
A test chamber surrounded by a coil (NS-SCT10R, Neuroscience Inc., Tokyo, Japan) was 
installed in a dim room at constant temperature (23±2°C). An animal was placed into the 
chamber and given acclimation period of 5 minutes. Measurements were conducted for 30 
minutes per day. Any movements of the magnet-implanted limb including abnormal 
behaviors related to spontaneous pain (e.g. lifting and licking the CCI limb) caused the 
changes in the electromagnetic field and generated a voltage, the amount of which was 
dependent on the speed and direction of magnet movement. The voltage generated in the coil 
was amplified and digitized via an interface unit (NS-SCTB16, Neuroscience Inc., Tokyo, 
Japan). Abnormal behaviors were automatically detected as spike waveforms, and counted by 
analytical software (MicroAct®; NS-SC-S100, Neuroscience Inc., Tokyo, Japan). The 
followings were set as analytical parameters for waveforms formed by movement of the 
limbs: range of frequency 2.5–20 Hz, threshold 0.01 V, minimum duration 0.09 seconds, 
shortest duration gap 0.03 seconds. 
Quantification of the degree of mechanical allodynia using the von-Frey filament test  
Mechanical allodynia was evaluated by the up-down method using von-Frey filaments 
 9 
according to the previously described method by Chaplan et al. [16]. An animal was placed in 
a plastic box with a metal mesh floor. After the adaptation period of 30 minutes, a filament 
was applied perpendicular to the sole of the ipsilateral limb with the pressure by which the 
filament was slightly bent. Withdrawal of CCI limb upon stimuli was regarded as a positive 
response. Eight filaments (0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0, and 15.0 g) were used. The 2.0 g 
filament was used first. When a positive response was observed, the next weaker filament 
was used for stimulation; if no response was observed, the next stronger filament was used. 
Two consecutive stimulations in which an animal’s reaction changed from negative to 
positive or from positive to negative was defined as the first 2 reactions, after which 4 
stimulations were consecutively applied based on the animal response. In cases where 
continuous positive and negative response were observed to the exhaustion of the filament set, 
values of 0.25g and 15.0g were applied respectively. According to the reaction pattern to 
these 6 stimulations, the 50% reaction threshold was calculated by the formula [16].  
Statistical analysis 
The number of limb movements including abnormal behaviors and the reaction threshold 
in the von-Frey filament test are reported as the mean ± standard error of the mean (SEM). 
Statistical analyses were performed using split-plot analysis of variance. Unpaired t-test was 
used as a post-hoc test. SPSS version 24 (GraphPad Software, Inc., La Jolla, CA, USA) was 
used for all analyses. P values less than 0.05 were considered statistically significant. 
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 Results 
All the CCI model rats displayed “normal movements” associated with walking and 
“abnormal movements” including lifting/guarding, flinching/shaking, and licking. The 
number of limb movements in the ADMSCs transplantation group (344 ± 53) and in the 
control group (354 ± 36), after CCI surgery and before ADMSCs transplantation or PBS 
injection, increased compared to that of 10 syngeneic rats without CCI surgery (80.5 ± 11.6) 
with the statistical significance. The reaction threshold in the ADMSCs transplantation 
group (3.70 ± 0.62) and in the control group (4.19 ± 0.4), after CCI surgery and before 
ADMSCs transplantation or PBS injection, decreased compared to that of 10 syngeneic rats 
without CCI surgery (14.19 ± 0.54) with the statistical significance. Unpaired t-test was used 
to check the result of CCI surgery. 
Those changes indicated that the CCI model rats were successfully established. No animals 
died during the experiments. All animals kept gaining weight over time even after the CCI 
surgery and ADMSCs transplantation. 
Assessment of spontaneous pain  
The number of limb movements in the ADMSCs transplantation group and the control 
group were as shown in Fig.1. Measurements were performed before ADMSCs 
transplantation and on 7-, 14-, 21-, 28-, 35-, and 42-day post-transplantation. Split-plot 
analysis of variance showed no interaction between measurement timing and groups and 
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showed a statistically significant difference in the number of limb movements between the 
ADMSCs transplantation group and the control group (p = 0.036). It suggested that 
statistically significant differences were observed between transplantation group and control 
group, irrespective of measurement timing. Unpaired t-test was performed as a post-hoc test. 
This analysis showed significant differences between the ADMSCs transplantation group and 
the control group on 21-, 28-, and 35-day post-transplantation (all of them, p < 0.05). These 
results suggest that ADMSCs transplantation reduced the number of spontaneous pain-related 
behaviors on and after 21-day post-transplantation. 
Quantification of the degree of mechanical allodynia  
The reaction threshold in the ADMSCs transplantation group and the control group were 
shown in Fig.2. The reaction threshold was evaluated before ADMSCs transplantation and on 
7-, 14-, 21-, 28-, 35-, and 42-day post-transplantation. Split-plot analysis of variance 
demonstrated an interaction between measurement timing and groups. Unpaired t-test as a 
post hoc test detected significant differences on 7-, 14-, 21-, 28-, 35-, and 42-day 
post-transplantation (all of them, p < 0.05). These results suggested that ADMSCs 
transplantation alleviated mechanical allodynia on and after 7-day post-transplantation. 
 
Discussion 
Several studies suggested that ADMSCs transplantation improves neuropathic pain in 
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animal models [9-12]. However, these studies evaluated the efficacy of ADMSCs 
transplantation by assessing only mechanical allodynia but not spontaneous pain. Murai et al. 
[17] noted differences in the effects of drugs on spontaneous and evoked pain-related 
behaviors in rats, and suggested that there are different mechanisms in spontaneous and 
evoked pain symptoms in neuropathic pain condition. Therefore, we think that to verify the 
efficacy of ADMSCs transplantation against neuropathic pain in clinical practice, it is 
pertinent to evaluate its efficacy against spontaneous pain, even in the animal experiments 
stage. 
The experimental models for neuropathic pain have been developed: (1) CCI model of 
Bennett and Xie [15]; (2) the tight ligation of the partial sciatic nerve model of the Seltzer et 
al. [18]; and (3) the tight ligation of spinal nerves model of Kim and Chung [19]. All three 
models mentioned above produce spontaneous pain and mechanical allodynia. In this study, 
we used the CCI model as a rat neuropathic pain model, because, in the previous studies, the 
CCI model was used to evaluate ADMSCs transplantation effects on neuropathic pain [9, 11, 
12]. 
We observed an improvement in mechanical allodynia on and after 7-day 
post-transplantation. This result is similar to that of previous studies in which ADMSCs were 
locally transplanted [10, 11]. Spontaneous pain-related behaviors, however, were significantly 
improved on and after 21-day post-transplantation, suggesting that different mechanisms 
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contribute to mechanical allodynia and spontaneous pain. It is currently unknown how 
ADMSCs improves neuropathic pain. In the previous study, ADMSCs administered into the 
subarachnoid space of CCI model rats were histologically found on the surface of the spinal 
cord and dorsal root ganglia [11]. These ADMSCs can directly modulate the inflammatory 
reactions and immune cells, which play important roles in nociception of pain and tissue 
regeneration. It is also suggested that MSCs modulate inflammatory and immune processes 
through paracrine release of soluble factors such as interleukin 10, leukemia inhibitory factor, 
and transforming growth factor-β [8]. In addition to these mechanisms, MSCs are known to 
induce antihyperalgesic effects through the activation of the endogenous opioid system. Guo 
W et al. hypothesized that the activation of peripheral opioid receptors plays a main role in 
inducing antihyperalgesic effects in the early stages of MSC transplantation, while the 
activation of central opioid receptors underlie the antihyperalgesic effects in the late stages of 
MSC transplantation [7]. 
While the effectiveness of morphine, an opioid agonist, in the treatment of neuropathic 
pain had been controversial, opioids have been recently used in the management of patients 
with neuropathic pain [20]. In CCI model rats, morphine reduced the number of spontaneous 
pain-related behaviors and alleviated mechanical allodynia at an s.c. dose of 3 mg/kg or 
greater [17]. However, clinical use of high-dose morphine carries a risk of adverse events 
including nausea, constipation, sleepiness, sedation, and respiratory depression. Given that 
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both MSCs transplantation and morphine improve neuropathic pain via modulation of the 
opioid system, our finding that MSCs transplantation reduced the number of spontaneous 
pain-related behaviors in CCI model rats is not inconsistent with theories suggested 
previously. ADMSCs transplantation may be a safer therapeutic approach for neuropathic 
pain than morphine. 
Although the safety of autologous MSCs transplantation is controversial, the fact that the 
number of clinical studies using autologous MSCs transplantation is increasing [21],  
indicating that MSCs transplantation techniques satisfy the safety standard in clinical 
practice. 
All clinical studies using transplantation of the stromal vascular fraction (SVF) and 
autologous fat for the treatment of neuropathic pain [22-26] have demonstrated 
improvements in spontaneous pain without any major complications. We propose that 
transplantation of cultured ADMSCs, ADMSCs purity of which is higher than that of SVF 
and autologous fat, may be more effective for improving pain than transplantation of SVF 
and autologous fat. 
This study has some limitations. First, we did not examine the effects of intravenous 
administration of ADMSCs for neuropathic pain. The intravenous administration of ADMSCs 
was reported as effective to alleviate neuropathic pain [9, 11, 12]. Second, while we verified 
the inhibitory effect of ADMSCs transplantation on pain behaviors, we did not examine the 
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histological or biochemical changes. This study, however, demonstrated that ADMSCs 
transplantation reduced the number of spontaneous neuropathic pain-related behaviors in a 
CCI rat model. This new finding may suggest that ADMSCs transplantation is effective 
treatment to spontaneous neuropathic pain, which is seen in almost all cases of neuropathic 
pain, in clinical practice.  
 
Conclusion 
The sufficiently effective treatment for the neuropathic pain is not established yet. 
ADMSCs transplantation emerges as a therapeutic option for the neuropathic pain. We 
evaluated the effects of ADMSCs transplantation on spontaneous pain and mechanical 
allodynia in CCI model rats. In this study, ADMSCs transplantation improved not only 
mechanical allodynia but also spontaneous pain. A possibility is suggested that ADMSCs 
transplantation is effective to mechanical allodynia and spontaneous pain of neuropathic pain 
in clinical practice. Further researches are necessary to confirm this possibility. 
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